Aardvark Therapeutics, Inc. Common Stock
Veridion Score
BETALOW CONF · 4/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is AARD moving today?
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
AARD overview
Related filings and maps
Congress activity in AARD
No receipt-qualified Congressional disclosure is present for AARD in the cached public ledger.
AARD contract awards, year to date.
Public federal awards linked to this ticker.
AARD lobbying filings, year to date.
Registered lobbying filings matched to Aardvark Therapeutics, Inc. Common Stock.
AAR CORP.
AAR CORP.
AAR CORP.